Board of Directors
Robert B. Cameron, M.D.
UCLA Medical School
Nicholas J. Vogelzang, M.D.
University of Chicago
M. Ann Abbe
Arlington, Texas
Michael Harbut, M.D., M.P.H.
Royal Oak, MI
Roger G. Worthington, Esq.
Dallas, Texas
Matthew Bergman, Esq.
Seattle, Washington
Susan Vento
St. Paul, Minnesota
Mouzetta Zumwalt-Weathers
Cary, North Carolina
Ulf Jungnelius M.D.
Pfizer, Inc.
In Memoriam
Congressman Bruce F. Vento
Science Advisory Board
Harvey Pass, M.D., Chairman
Karmanos Cancer Institute
Victor Roggli, M.D.
Duke University
Robert N. Taub, M.D.
Columbia University
Lary A. Robinson, M.D.
H. Lee Moffit Cancer Center
Steve Hahn, M.D.
University of Pennsylvania
Joseph R. Testa, Ph. D.
Fox Chase Cancer Center
Claire Verschraegen, M.D.
University of New Mexico
Eric Vallieres, M.D.
Swedish Cancer Institute
Dan Miller, M.D.
Emory University
Raphael Bueno, M.D.
Harvard/Brigham and Women's
Hedy Lee Kindler, M.D.
University of Chicago
W. Roy Smythe, M.D.
Texas A&M
Executive Director
Christopher E. Hahn
MARF, inc.
1609 Garden Street
Santa Barbara, CA 93101
tel (805) 560-8942
fax (805) 560-8962
c-hahn@marf.org
http://www.marf.org
|
Our mission is to eradicate mesothelioma as a life-ending
disease.
August 27, 2004
VIA REGULAR U.S. MAIL,
TELECOPY (212) 644-6755,
and E-MAIL (ei@capdale.com)
Elihu Inselbuch, Esq.
Caplin & Drysdale
399 Park Ave.
New York, NY 10022
|
Re:
|
|
Funding Medical Research on Prevention,
Detection, Treatment and Cure of Asbestos Cancer from
Asbestos Debtors' Trust
|
Dear Mr. Inselbuch:
Fred Baron and Peter Kraus suggested I contact you. I am
the Founding Director of the Mesothelioma Applied Research
Foundation (MARF), the only 501(c)(3) charity whose mission
is to eradicate mesothelioma as a life-ending disease. In
2002, we offered Judge Wolin our expertise in assisting the
Court evaluate the singularly devastating financial and
medical hardships endured by mesothelioma patients
(see attached letter).
We are addressing this letter to you in your capacity as
counsel for asbestos victims' creditors in several
ongoing Chapter 11 reorganizations. The problem is familiar
to you: billions of dollars have been consumed by asbestos
litigation, millions of Americans walk around with
dangerous levels of asbestos fibers in their lungs,
thousands have died from mesothelioma, and the cancer is
predicted to peak in 2025. About 3,000 Americans are
diagnosed with this fatal cancer annually, of which 32%
contracted the disease while serving in the U.S. Navy or
working in Navy shipyards. Despite the money spent and the
lives lost, neither industry nor the government has ever
embarked on a serious mission to fund medical research
designed to prevent, detect, treat or cure mesothelioma.
On behalf of present and future mesothelioma patients, we
are asking for your help in solving this socio-economic,
legal and public health crisis. A coalition of doctors,
trial lawyers and industry lawyers (viz. Owens Corning
Fiberglas and W.R. Grace) formed MARF in 1999. We agreed
that the time was long overdue to spend more of our energy
on fixing the problem, and less time on fixing blame
OCF pledged $1 million to
MARF, of which it paid $100,000 before it sought
bankruptcy protection. W.R. Grace had also indicated that
it too would donate handsomely to MARF prior to its going
into Chapter 11. There is, we believe, a consensus among
competing factions to unite against the common enemy.
Today, we understand that OCF has already burned through
nearly $100 million in bankruptcy costs (mainly legal
fees), while WRG has paid out over $55 million. And the
meter is running. Assuming a 6-year detour in the
bankruptcy courts, the anticipated costs are projected to
exceed $186 and $102 million for OCF and WRG, respectively.
The anticipated value of the bankruptcy settlement trusts
for OCF and WRG are projected to exceed $3 and $1 billion,
respectively. Naturally, MARF regrets that it most likely
will never collect the balance of the debt owed by OCF --
money that would have been invested directly into
peer-reviewed research grants targeted at preventing,
treating and curing mesothelioma.
We understand that in the near future, once the trust
distribution plans are approved for a dozen or so of the
largest Chapter 11 reorganizations, there is likely to be a
combined pool of between $11 and $22 billion dedicated to
compensating asbestos victims. We believe that in addition
to maximizing compensation for asbestos cancer claimants,
trustees should also have a duty to invest the trust money
in a medical program designed to prolong the survival of
current asbestos cancer victims and prevent the existence
of future cancer claimants.
We would like to speak to you about whether the trustees,
in your view, have any legal authority to allocate a
portion of the settlement trust to medical research for the
detection, prevention and cure of asbestos cancer. Is there
a scenario within the existing web of rules, court rulings
and codes that would permit trustees to fund peer-reviewed
medical research?
If not, what changes need to be made, at any level, that
would authorize if not encourage trustees to invest a
portion of the trust in medical research that would
potentially help reduce the quantity and quality of future
claims? We realize that the short answer, based on
precedent and the black letter of the law, may ironically
prevent trustees from dedicating hard fought trust dollars
to help prevent or alleviate the suffering of present and
future beneficiaries. But if asbestos victims cannot count
on the trustees to hold the debtors accountable for
cleaning up the mess they have wrought, who can? Who will
help close Pandora's box of relentless pain and misery?
We believe that mesothelioma is presumed to be
"incurable" only because there has never been a
concerted effort by the asbestos industry, the government,
the insurance companies and the victims and their lawyers
to fund the medical research necessary to cure it. On
behalf of mesothelioma patients, we are looking for your
guidance and support.
My phone number is (949) 496-5918.
Sincerely,
Roger G. Worthington
Enclosures
cc: Peter Lockwood, Esq.
|